^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) +
    capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Invasive Breast Cancer: HER2 Negative….SYSTEMIC THERAPY REGIMENS FOR RECURRENT UNRESECTABLE (LOCAL OR REGIONAL) OR STAGE IV (M1) DISEASE....Useful in Certain Circumstances:...Docetaxel/capecitabine
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

    Excerpt:
    ...- Histologically or cytologically proven locally advanced or advanced HER-2 negative breast cancer;...
    Trial ID:
    NCT02947061
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

    Excerpt:
    ...- HER2-negative metastatic breast cancer...
    Trial ID:
    NCT01777945
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

    Excerpt:
    ......
    Trial ID:
    NCT02897050
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC

    Excerpt:
    ...- Histologically confirmed and documented HER2-negative metastatic breast cancer....
    Trial ID:
    CAMELLIA
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Cancer
    Title:

    Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial

    Published date:
    12/28/2022
    Excerpt:
    This trial assessed the efficacy and safety of the TX regimen (docetaxel and capecitabine)... in locally advanced or high risk early HER2-negative breast cancer…14 patients in the TX group achieved a pCR, and nine patients in the TE group achieved a pCR (25.9% vs. 15.3%), with a not significant difference of 10.6% (95% CI -6.0-27.3%; P = 0.241). In a subgroup with high Ki-67 score, TX increased the pCR rate by 24.2% (95% CI 2.2-46.1%; P = 0.029)....The anthracycline-free TX regimen yielded comparable pCR and long-term survival rates to the TE regimen.
    DOI:
    10.1186/s12885-022-10439-0